The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2025 | Key updates on ctDNA and immunotherapy in colorectal cancer
Sakti Chakrabarti, MD, University Hospitals Seidman Cancer Center, Cleveland, OH, emphasizes the role of circulating tumor DNA (ctDNA) in colorectal cancer care. Updates from BESPOKE CRC (NCT04264702) confirm ctDNA as a robust biomarker for minimal residual disease, while findings from the NEO (NCT03259035) highlight its utility in guiding organ preservation strategies in patients with early-stage rectal cancer. These additions further strengthen the growing body of evidence supporting ctDNA-guided decision making. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
